ENOV Strangle Strategy
ENOV (Enovis Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
ENOV (Enovis Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $1.42B, a beta of 1.45 versus the broader market, a 52-week range of 19.14-34.28, average daily share volume of 1.1M, a public-listing history dating back to 2008, approximately 8K full-time employees. These structural characteristics shape how ENOV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.45 indicates ENOV has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on ENOV?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
ENOV snapshot
As of August 14, 2026, spot at $26.22, ATM IV 61.40%, IV rank 24.86%, expected move 17.60%. The strangle on ENOV below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on ENOV specifically: ENOV IV at 61.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a ENOV strangle, with a market-implied 1-standard-deviation move of approximately 17.60% (roughly $4.62 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ENOV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ENOV should anchor to the underlying notional of $26.22 per share and to the trader's directional view on ENOV stock.
ENOV strangle setup
The ENOV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ENOV at $26.22 on that close, the first option leg uses a $27.53 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ENOV chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ENOV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $27.53 | N/A |
| Buy 1 | Put | $24.91 | N/A |
ENOV strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ENOV strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ENOV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ENOV
Strangles on ENOV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ENOV chain.
ENOV thesis for this strangle
The market-implied 1-standard-deviation range for ENOV extends from approximately $21.60 on the downside to $30.84 on the upside. A ENOV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ENOV IV rank near 24.86% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ENOV at 61.40%. As a Healthcare name, ENOV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ENOV-specific events.
ENOV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ENOV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ENOV alongside the broader basket even when ENOV-specific fundamentals are unchanged. Always rebuild the position from current ENOV chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ENOV?
- A strangle on ENOV is the strangle strategy applied to ENOV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ENOV stock at $26.22 on the most recent close, the strikes shown on this page are snapped to the nearest listed ENOV chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are ENOV strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ENOV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 61.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ENOV strangle?
- The breakeven for the ENOV strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ENOV market-implied 1-standard-deviation expected move in the same options snapshot is approximately 17.60%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ENOV?
- Strangles on ENOV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ENOV chain.
- How does current ENOV implied volatility affect this strangle?
- ENOV ATM IV is at 61.40% with IV rank near 24.86%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.